TIME FOR LIFE

BEVACIZUMAB

  • An angiogenesis inhibitor, a drug that slows the growth of new blood vessels. Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A)
  • Bevacizumab is approved to treat metastatic colorectal cancer, metastatic HER2-negative breast cancer, certain lung cancer, metastatic kidney cancer, ovarian and cervical cancers
  • Bevacisumab` inclusion into chemotherapy regimens significantly improves the effectiveness of treatment